The German Society for Pain Medicine (DGS) has announced new clinical studies on the use of medical cannabis. This was announced by DGS President Dr. Richard Ibrahim at the Medical Cannabis Congress in Berlin.

According to the information, around 15 million people in Germany suffer from chronic pain, for which conventional treatments are often not sufficient. Medical cannabis is increasingly being used for indications such as neuropathic pain, chronic non-tumor pain, tumor pain, MS spasticity as well as loss of appetite and cachexia.

The newly founded DGS initiative “Clinical Trials” comprises three projects: a study on fibromyalgia with 225 participants (start September 2026), a large study on chronic spine, back and osteoarthritis pain with over 1,500 participants (start June 2026) and a study on chronic pain with a standardized inhalation system.

At the same time, the DGS is working on a new curriculum “Cannabis Competence in Pain and Palliative Medicine” for the targeted further training of doctors and non-medical professionals. In addition, the existing practice guideline “Cannabis in Pain Medicine” will be further developed and is to be presented at the DGS Innovation Forum in Kassel on 20 November 2026.

Ibrahim emphasized that reliable data is necessary to better classify medical cannabis in pain medicine. With its more than 4,000 members, 16 national companies and 123 pain centers, the DGS has a strong network to advance health care research and improve the quality of pain care nationwide.

Read Also:

Psychosis: Cannabis use changes DNA – MedLabPortal

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability ected.